Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352584 | 0.89 | MEN1 (0.56) | GAAALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1753925 | 0.86 | GAA (0.70) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL8864575 | 0.86 | CYP1A2 (0.54) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL14816847 | 0.83 | HDAC3 (0.64) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL23540018 | 0.83 | RXFP1 (0.53) | GAAALDH1A1CDK2KMT2ASMN1; SMN2 | |
| SCHEMBL9843748 | 0.83 | GAA (0.66) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL27985505 | 0.82 | GAA (0.59) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL5804257 | 0.81 | GAA (0.63) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL1193345 | 0.81 | NPC1 (0.63) | GAAALDH1A1HDAC3HDAC1HDAC2 | |
| SCHEMBL5804254 | 0.81 | GAA (0.63) | GAAALDH1A1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0626380-B1 | N-(4-Fluorophenyl)-heteroaryloxyacetamide as herbicides | BAYER AG (DE) | 1999-01-13 | — | — | EP | claimed |
| EP-0626380-A1 | N-(4-Fluorophenyl)-heteroaryloxyacetamide as herbicides | BAYER AG (DE) | 1994-11-30 | — | — | EP | claimed |
| JP-7048361-A | — | — | None | — | — | JP | disclosed |
| EP-3710444-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-10676424-B2 | Trifluoromethoylation of arenes via intramolecular trifluoromethoxy group migration | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190016670-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-01-17 | — | — | US | disclosed |
| WO-2016019588-A1 | OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE | THE BROAD INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-0626380-B1 | N-(4-Fluorophenyl)-heteroaryloxyacetamide as herbicides | BAYER AG (DE) | 1999-01-13 | — | — | EP | disclosed |
| JP-H0748361-A | N-(4-FLUOROPHENYL)HETEROARYLOXYACETAMIDE AS HERBI-CIDE | BAYER AG | 1995-02-21 | — | — | JP | disclosed |
| EP-0626380-A1 | N-(4-Fluorophenyl)-heteroaryloxyacetamide as herbicides | BAYER AG (DE) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016670-A1 | TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION | AHR, ARSA, ALK | GAA 4070/4885ALDH1A1 599/4885HDAC3 388/4885 |
| US-10676424-B2 | Trifluoromethoylation of arenes via intramolecular trifluoromethoxy group migration | AHR, AFF2, AFF4 | GAA 4240/4885ALDH1A1 1123/4885HDAC3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.